Blue Jet Healthcare Ltd.
NSE: BLUEJET · Pharmaceuticals
Snapshot
Unlock Blue Jet Healthcare Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Blue Jet Healthcare Limited is a specialty pharmaceutical company focused on the manufacturing of contrast media intermediates, high-intensity sweeteners like saccharin, and niche pharmaceutical intermediates. The company operates as a key supplier in the global healthcare supply chain, providing both products and CDMO/CMO development services.
Business Model
The company generates revenue through the manufacturing and sale of specialised chemical intermediates and APIs, leveraging a B2B model to serve global pharmaceutical and healthcare clients. It further enhances its value proposition by offering integrated contract development and manufacturing services.
Growth Outlook
Growth is driven by the expansion of its CDMO/CMO service offerings and the increasing global demand for contrast media and niche pharmaceutical ingredients. The company continues to leverage its established international presence to capture market share in regulated pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety standards from international health authorities, where non-compliance could lead to product recalls or facility bans.
- Customer Concentration. A significant portion of revenue may be derived from a limited number of large pharmaceutical clients, making the company vulnerable to changes in their procurement strategies.
- Foreign Exchange Volatility. As a company with significant international operations, fluctuations in currency exchange rates can materially impact reported financial performance and profit margins.
- Raw Material Price Fluctuations. Volatility in the cost of key chemical raw materials and energy can adversely affect the company's manufacturing costs and overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Blue Jet Healthcare Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹886 Cr
TTM · standalone
NET PROFIT
₹235 Cr
TTM · standalone
EPS
₹13.55
TTM · standalone
RETURN ON EQUITY
18.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
25.0%
TTM · standalone
P/E
42.1x
Q1 FY27 · standalone
EV/EBITDA
30.9x
Q1 FY27 · standalone
EBITDA MARGIN
39.2%
TTM · standalone
NET PROFIT MARGIN
26.7%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Blue Jet Healthcare Ltd.BLUEJET | ₹10,785 Cr | 42.05 | 30.92 | -27.5% | 39.2% | 18.8% | 25.0% | -19.6% |
Corona RemediesCORONA | ₹12,844 Cr | 64.54 | 39.52 | — | 22.2% | 26.6% | 31.7% | — |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | ₹12,052 Cr | 40.20 | 16.77 | 9.2% | 15.6% | 9.2% | 13.8% | +64.4% |
Strides Pharma Science LimitedSTAR | ₹9,767 Cr | 15.92 | 10.37 | 7.3% | 21.7% | 22.4% | 24.5% | +20.0% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | ₹9,677 Cr | 36.38 | 24.67 | 31.2% | 39.2% | 87.9% | 107.5% | -19.4% |
Procter & Gamble Health LimitedPGHL | ₹9,395 Cr | 26.33 | 19.08 | 44.9% | 33.7% | 67.2% | 84.2% | -12.4% |
As of Q1 FY27
Financials
Blue Jet Healthcare Ltd.
NSE: BLUEJET · Pharmaceuticals
Snapshot
Unlock Blue Jet Healthcare Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Blue Jet Healthcare Limited is a specialty pharmaceutical company focused on the manufacturing of contrast media intermediates, high-intensity sweeteners like saccharin, and niche pharmaceutical intermediates. The company operates as a key supplier in the global healthcare supply chain, providing both products and CDMO/CMO development services.
Business Model
The company generates revenue through the manufacturing and sale of specialised chemical intermediates and APIs, leveraging a B2B model to serve global pharmaceutical and healthcare clients. It further enhances its value proposition by offering integrated contract development and manufacturing services.
Growth Outlook
Growth is driven by the expansion of its CDMO/CMO service offerings and the increasing global demand for contrast media and niche pharmaceutical ingredients. The company continues to leverage its established international presence to capture market share in regulated pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety standards from international health authorities, where non-compliance could lead to product recalls or facility bans.
- Customer Concentration. A significant portion of revenue may be derived from a limited number of large pharmaceutical clients, making the company vulnerable to changes in their procurement strategies.
- Foreign Exchange Volatility. As a company with significant international operations, fluctuations in currency exchange rates can materially impact reported financial performance and profit margins.
- Raw Material Price Fluctuations. Volatility in the cost of key chemical raw materials and energy can adversely affect the company's manufacturing costs and overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Blue Jet Healthcare Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹886 Cr
TTM · standalone
NET PROFIT
₹235 Cr
TTM · standalone
EPS
₹13.55
TTM · standalone
RETURN ON EQUITY
18.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
25.0%
TTM · standalone
P/E
42.1x
Q1 FY27 · standalone
EV/EBITDA
30.9x
Q1 FY27 · standalone
EBITDA MARGIN
39.2%
TTM · standalone
NET PROFIT MARGIN
26.7%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27